ClinicalTrials.gg
Not yet recruitingNCT04501016Stepped CareUpdated Aug 6, 2020

A Stepped Care Approach to Treating Tobacco Use in Rural Veterans

A Phase 2/3 interventional study of Tailored behavioral counseling and Tobacco cessation pharmacotherapy in Tobacco Cessation, sponsored by Iowa City Veterans Affairs Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-06.

Sponsored by Iowa City Veterans Affairs Medical Center · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2021, 5 years 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 190 studies in Tobacco Use Cessation with a site in United States — 30 open to participants now, 41 under way, 2 of them phase 3. Tobacco Use Cessation · United States.

Planned enrollment
124th of 184
100 · median 213
Started
2020
with 8 others
Phase 2/3
5 of 190
1 open now
Primary completion
2021-08
later than 0 of 40 live
Registered
132nd of 190
by date

Among the 190 studies in Tobacco Use Cessation with a site in United States, this one is the 124th largest by planned enrollment of the 184 interventional ones that give a count, is one of 9 that started in 2020, is one of 5 in phase 2/3, reaches primary completion later than 0 of the 40 other live ones, and was the 132nd registered.

Tobacco Use Cessation

276 studies on the registry are indexed under Tobacco Use Cessation; 45 are open to participants now.

Browse Tobacco Use Cessation studies →

Open to participants now

30 of the 190 studies in Tobacco Use Cessation with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 23 Tobacco Use Cessation studies recruiting now, 16 (70%) set no upper age limit and 6 (26%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Tobacco Use Cessation with a site in United States, or all of them as a file.
02

Study summary

Tobacco use remains prevalent among Veterans. Although effective smoking cessation interventions exist, long-term term quit rates remain sub-optimal. The project will investigate the feasibility of a stepped care approach to treating tobacco use that includes enhancements based on initial response to treatment to augment the investigators' existing tailored tobacco treatment intervention.

Read the detailed description

Rural tobacco users (cigarette smokers, smokeless tobacco users, and users of other forms of tobacco) from the Iowa City VA Health Care System will be proactively recruited using information obtained from the electronic medical record. All participants will receive the investigators' tailored, six session smoking cessation intervention developed over a series of projects funded by ORH. This includes a counseling protocol tailored to tobacco users' individual needs and associated risk factors as well as pharmacotherapy selected using shared decision making. Participants who are unable to quit initially will be provided with enhanced counseling based on self-monitoring and scheduled reduced smoking. Those who are able to quit using tobacco during the initial treatment phase will be given an extended, four-session counseling protocol that incorporates new content based on established interventions from positive psychology in an effort to reduce relapse.

03

Conditions studied

  • Tobacco Cessation

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Use tobacco (cigarettes, smokeless tobacco, pipes, cigars, hookah) on a daily basis
  • Be willing to make a quit attempt in the next 30 days
  • Able to provide
  • Have access to a telephone
  • Have a stable residence,

Exclusion criteria

Exclusion Criteria:

  • Planning to move within the next 6 months
  • Terminal illness
  • Unstable psychiatric disorder (e.g., acute psychosis)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Tailored Intervention

    Tailored behavioral counseling combined with tobacco cessation pharmacotherapy.

    Behavioral: Tailored behavioral counseling · Drug: Tobacco cessation pharmacotherapy

Interventions

  • BehavioralTailored behavioral counseling

    Participants will initially receive a six-session telephone intervention. Standard cognitive behavioral treatment strategies will be included. Participants will be screened for elevated depressive symptoms, risky alcohol use, and concerns about weight and and offered supplemental behavioral counseling related to these issues as appropriate. Those that are unable to quit tobacco initially will receive an enhanced, four-session counseling module focused on reduced scheduled smoking. Those who do quit tobacco use initially will receive four sessions of extended counseling based on positive psychology intervention strategies.

  • DrugTobacco cessation pharmacotherapy

    Pharmacotherapy will be selected based on medical and psychiatric history and potential interactions with other current medications combined with shared decision making. Options will include nicotine gum (2 and 4 mg), nicotine lozenge (2 and 4 mg), nicotine patch (7, 14, and 21 mg), bupropion (150 mg twice daily) and varenicline (1 mg twice daily). Monotherapy and combination therapy options will be provided.

06

What researchers measure

Primary outcomes

  1. Tobacco cessation

    7-day point prevalence tobacco cessation

    Time frame: 6 months

Secondary outcomes

  1. Tobacco cessation

    7-day point prevalence tobacco cessation

    Time frame: 3 months

  2. Salivary cotinine levels (in ng/ml)

    Salivary cotinine

    Time frame: 6 months

Other outcomes

  1. Level of satisfaction with the intervention as measured according to a five-point scale (extremely, very, moderately, slightly, not at all)

    Self-reported satisfaction with the intervention according to the dimensions of usefulness, convenience, difficulty, liking, and helpfulness using five response options (extremely, very, moderately, slightly, not at all) using a scale developed specifically for the project.

    Time frame: 3 months

07

Study locations

1 site
  • Iowa City VA Healthcare System
    Iowa City, Iowa 52246, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2020; primary completion for Aug 2021, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2020
First posted
Aug 6, 2020
StartEst.
Sep 2020
Primary completionEst.
Aug 2021
CompletionEst.
Sep 2023
Last update
Aug 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04501016
Lead sponsor
Iowa City Veterans Affairs Medical Center
Responsible party
Mark Vander Weg (Core Investigator, Iowa City Veterans Affairs Medical Center) — Principal investigator
First posted
Aug 6, 2020
Start date
Sep 2020 (estimated)
Primary completion
Aug 2021 (estimated)
Completion
Sep 2023 (estimated)
Last update
Aug 6, 2020

Study contacts

Theresa Morano, MS
Contact
theresa.morano@va.gov
319-338-0581 ext. 63-7663
Mark Vander Weg, PhD
principal investigator · Iowa City VA Health Care System

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion